Mesoblast
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 73
- Market Cap
- $733.9M
- Website
- http://www.angioblast.com
- Introduction
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Clinical Trials
38
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (32 trials with phase data)• Click on a phase to view related trials
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
- Conditions
- Grade B Acute Graft Versus Host DiseaseGrade C Acute Graft Versus Host DiseaseGrade D Acute Graft Versus Host Disease
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02652130
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸CHOC Children's Hospital of Orange County, Orange, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02336230
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 566
- Registration Number
- NCT02032004
- Locations
- 🇺🇸
Mesoblast Investigational Site 10757 - Cardiology, P.C., Birmingham, Alabama, United States
🇺🇸Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center, Gilbert, Arizona, United States
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT01781390
Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mesoblast, Inc.
- Registration Number
- NCT01510431
- Locations
- 🇺🇸
Unviersity of California, San Francisco, San Francisco, California, United States
🇺🇸Stormont-Vail, Topeka, Kansas, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
NextCell Pharma Strengthens Commercial Strategy with Appointment of MSC Therapy Expert Dr. Eric Strati
NextCell Pharma has appointed Dr. Eric Strati, former executive at Takeda, Mesoblast, and Novartis, to its Board of Advisors to advance commercial strategy for ProTrans, its type 1 diabetes cell therapy.
Mesoblast's Ryoncil Receives US FDA Orphan Drug Approval, Driving 15% Share Price Surge
Mesoblast received US FDA orphan drug approval for Ryoncil, granting seven years of market exclusivity and driving a 15% share price increase over one week.
Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved
The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.
FDA Roundup: Approvals, Breakthrough Designations, and Clinical Holds in Neurology and Rare Diseases
• The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels. • Tolebrutinib received breakthrough therapy designation for non-relapsing secondary progressive multiple sclerosis based on phase 3 trial results showing delayed disability progression. • The FDA placed a clinical hold on PepGen’s PGN-EDO51 phase 2 study for Duchenne muscular dystrophy, pending further clarification from the agency.
Mesoblast Receives FDA Approval for First MSC Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
• Mesoblast's mesenchymal stromal cell (MSC) therapy has gained FDA approval for steroid-refractory acute graft-versus-host disease (SR-aGVHD). • This approval marks a significant advancement in regenerative medicine, highlighting the potential of MSC therapies. • Pluri Inc. congratulates Mesoblast, emphasizing the importance of this milestone for the entire field of cellular medicine. • The FDA's decision underscores the opportunity to accelerate the development of MSC-based therapies globally, according to Pluri.
FDA Approves Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-versus-Host Disease
The FDA has approved Ryoncil (remestemcel-L-rknd) as the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients.
Mesoblast's Ryoncil Receives FDA Approval for Pediatric Blood Disorder Treatment
Mesoblast's Ryoncil has been approved by the FDA for treating children with a severe blood disorder, marking a significant milestone for the company.
ASX Biotechs Gear Up for Critical Phase III Trial Results in 2025
Several ASX-listed biotech companies are anticipating crucial Phase III clinical trial results in 2025, which could significantly impact their market value and future prospects.
Revascor Shows Promise in DREAM-HF Trial for Ischemic Heart Failure
Mesoblast's Revascor demonstrated improved survival and reduced major morbidity in high-risk ischemic heart failure patients with inflammation.
FDA Approves Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric SR-aGVHD
The FDA has approved Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States.